IL165568A0 - N,N-disubstituted diazocycloalkanes useful for thetreatment of CNS disorders due to serotonergic - Google Patents

N,N-disubstituted diazocycloalkanes useful for thetreatment of CNS disorders due to serotonergic

Info

Publication number
IL165568A0
IL165568A0 IL16556804A IL16556804A IL165568A0 IL 165568 A0 IL165568 A0 IL 165568A0 IL 16556804 A IL16556804 A IL 16556804A IL 16556804 A IL16556804 A IL 16556804A IL 165568 A0 IL165568 A0 IL 165568A0
Authority
IL
Israel
Prior art keywords
thetreatment
serotonergic
useful
cns disorders
disorders due
Prior art date
Application number
IL16556804A
Other languages
English (en)
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of IL165568A0 publication Critical patent/IL165568A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL16556804A 2002-06-14 2004-12-06 N,N-disubstituted diazocycloalkanes useful for thetreatment of CNS disorders due to serotonergic IL165568A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001328A ITMI20021328A1 (it) 2002-06-14 2002-06-14 Nuove piperazine 1,4 - disostituite
PCT/EP2003/006280 WO2003106444A1 (en) 2002-06-14 2003-06-16 N,n-disubstituted diazocycloalkanes useful for the treatment of cns disorders due to serotonergic dysfunction

Publications (1)

Publication Number Publication Date
IL165568A0 true IL165568A0 (en) 2006-01-15

Family

ID=29727277

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16556804A IL165568A0 (en) 2002-06-14 2004-12-06 N,N-disubstituted diazocycloalkanes useful for thetreatment of CNS disorders due to serotonergic

Country Status (19)

Country Link
US (1) US20060148821A1 (ja)
EP (1) EP1515961A1 (ja)
JP (1) JP2005538063A (ja)
CN (1) CN1662516A (ja)
AU (1) AU2003276979A1 (ja)
BR (1) BR0311805A (ja)
CA (1) CA2489450A1 (ja)
EA (1) EA007503B1 (ja)
HR (1) HRP20050034A2 (ja)
IL (1) IL165568A0 (ja)
IT (1) ITMI20021328A1 (ja)
MX (1) MXPA04012602A (ja)
NO (1) NO20050146L (ja)
NZ (1) NZ537469A (ja)
PL (1) PL372531A1 (ja)
RS (1) RS108904A (ja)
TW (1) TW200400947A (ja)
WO (1) WO2003106444A1 (ja)
ZA (1) ZA200500318B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
IN2012DN01453A (ja) 2009-08-20 2015-06-05 Novartis Ag

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293804B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Diarilalchilpiperazine attive sulle basse vie urinarie
JP2001512110A (ja) * 1997-08-01 2001-08-21 レコルダチ エッセ．ア．，ケミカル アンド ファーマシューティカル カンパニー １，４−ジ置換ピペラジン
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors

Also Published As

Publication number Publication date
NO20050146D0 (no) 2005-01-11
NO20050146L (no) 2005-03-14
CN1662516A (zh) 2005-08-31
WO2003106444A8 (en) 2004-08-12
EA007503B1 (ru) 2006-10-27
US20060148821A1 (en) 2006-07-06
JP2005538063A (ja) 2005-12-15
EA200500023A1 (ru) 2005-06-30
PL372531A1 (en) 2005-07-25
ZA200500318B (en) 2006-07-26
AU2003276979A1 (en) 2003-12-31
WO2003106444A1 (en) 2003-12-24
MXPA04012602A (es) 2005-09-30
TW200400947A (en) 2004-01-16
NZ537469A (en) 2006-07-28
HRP20050034A2 (en) 2005-08-31
RS108904A (en) 2007-02-05
EP1515961A1 (en) 2005-03-23
CA2489450A1 (en) 2003-12-24
ITMI20021328A1 (it) 2003-12-15
BR0311805A (pt) 2005-03-15

Similar Documents

Publication Publication Date Title
PL376524A1 (pl) Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 i sposób ich wytwarzania
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
TW200407305A (en) Novel compounds
WO2005013914A3 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
AU2003276537A8 (en) Process for conversion of biomass
ZA200702523B (en) Process for the purification of 1,4-butanediol
IL164516A0 (en) 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors
IL180513A0 (en) Process for synthesis of 4-4'-diamino-diphenyl-sulfone
HUP0302444A2 (hu) Eljárás nitrogéntartalmú heterociklusos vegyületek monometilezésére
MX2007003922A (es) Nuevas propenonas ciclicas y aciclicas para tratar trastornos del sistema nervioso central.
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
TWI367215B (en) Method for the preparation of purified elastomers from solution
IL165568A0 (en) N,N-disubstituted diazocycloalkanes useful for thetreatment of CNS disorders due to serotonergic
EP1404308A4 (en) TREATMENT OF SECONDARY DISORDERS CAUSED BY ORGANIC DEFICIENCIES
HRP20030965A2 (en) Process for production of (s)-n-pentanoyl-n-[[2'-(
GB0229033D0 (en) Purification of nanotubes
EP1547993A4 (en) PROCESS FOR PREPARING SPIROFLUORENOLS
AU2003250801A8 (en) Method for the production of endohedral fullerenes
AU2002247949A1 (en) Process for synthesis of trans-alkenoic acid, use thereof
PL1656358T3 (pl) Trwały polimorf mesylanu bifeprunoksu
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
AU2003239967A1 (en) Compound for the treatment of cns disorders
EG24122A (en) Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolines
EP1553073A4 (en) PROCESS FOR PREPARING 1,2,4-BUTANTRIOL
HK1082751A1 (en) Process for the purification of tnf-binding protins using imac